Answers are grounded in this paper and cite their sources.
Introduction Real-world data on dupilumab for moderate-to-severe atopic dermatitis (AD) in Latin America remain limited; therefore, we evaluated the real-world effectiveness and safety of dupilumab over 24 and 48 weeks in pediatric and adult patients in Colombia. Methods This observational, retrospective cohort included patients aged ≥6 years initiating dupilumab between 2020 and 2024 within a large integrated healthcare system. Clinician-reported (SCORAD, EASI) and patient-reported outcomes (DLQI, ADCT, POEM) were assessed at baseline and during routine follow-up, with primary evaluations at weeks 24 and 48, and analyzed using linear mixed-effects models. Therapeutic targets and minimal clinically important differences were assessed in paired datasets. Safety events were obtained from routine clinical documentation. Results A total of 547 patients met eligibility criteria (51.9% male; children 8.4%, adolescents 22.3%, adults 69.3%). Dupilumab was associated with reductionsacross all outcomes at weeks 24 and 48. At week 24, reductions were−59.3% in SCORAD, −71.9% in EASI, −66.8% in DLQI/CDLQI, −64.0% in ADCT and −60.0% in POEM (all p < 0.001), and were sustained or greater at week 48 (−65.2%, −79.3%, −67.1%, −66.4% and −66.8%, respectively). At week 48, 63.5% achieved EASI-75% and 36.5% achieved EASI-90. Improvements were consistent across age groups; adverse reactions were infrequent and mostly mild, most commonly headache and skin rash. Conclusion Dupilumab demonstrated robust, durable clinical benefits and a favorable safety profile in routine practice, supporting its effectiveness in diverse real-world populations.
No takes yet. Share an insight, caveat, or question.
Bolaños-López et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: